The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2

This publication has 20 references indexed in Scilit:

• Suppression of lymphocyte proliferation by a retroviral p15E-derived hexapeptide
  European Journal of Immunology, 1992
• Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
  European Journal Of Cancer, 1992
• Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study
  European Journal of Cancer and Clinical Oncology, 1991
• Comparison of transforming growth factor β and a human tumour-derived suppressor factor
  Cancer Immunology, Immunotherapy, 1991
• Autoantibodies to cytokines - friends or foes?
  Immunology Today, 1990
• A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2
  Cancer Treatment Reviews, 1989
• Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients
  Cancer Treatment Reviews, 1989
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.
  The Journal of Experimental Medicine, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985